title: Umeclidinium for treating COPD: an evaluation of pharmacologic properties, safety and clinical use.
abstract: BACKGROUND
  Umeclidinium (UMEC) is a long-acting inhaled antagonist of muscarinic cholinergic receptors. The FDA approved UMEC for maintenance treatment of chronic obstructive pulmonary disease (COPD) in 2013 and it became available for commercial use as a single agent in 2014. After tiotropium, this is the only other once daily LAMA available for COPD patients.
  
  
  METHODS
  In this article, we have comprehensively reviewed the pharmacokinetic properties and analyzed the currently available randomized controlled trials on the efficacy and safety profile of UMEC. We have discussed the current clinical application of UMEC and its future implication.
  
  
  CONCLUSIONS
  UMEC is the newer long-acting antimuscarinic agent (LAMA) that has demonstrated significant improvement in lung function and improved the quality of life in moderate-to-severe COPD patients. It is suitable for once daily dosing, has low anticholinergic side effects and is well tolerated. Overall, it is a safe, effective and convenient LAMA for maintenance therapy in COPD patients.
authors.affiliation: New York Medical College/Westchester Medical Center, Division of Pulmonary, Critical Care, and Sleep Medicine , Valhalla, NY, 10595 , USA +1 914 493 7518 ; +1 914 493 6987 ; rajee07@gmail.com.
authors.forename: Rajapriya
authors.initials: R
authors.lastname: Manickam
authors.forename: Amit
authors.initials: A
authors.lastname: Asija
authors.forename: Wilbert S
authors.initials: WS
authors.lastname: Aronow
mesh_terms: D000280:Administration, Inhalation; D000818:Animals; D004334:Drug Administration Schedule; D006801:Humans; D008168:Lung / Q000187:drug effects* / Q000503:physiopathology; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D011812:Quinuclidines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: C573971:GSK573719; D018727:Muscarinic Antagonists; D011812:Quinuclidines
keywords: COPD; LAMA; bronchodilators; umeclidinium